乐普LEPU品牌怎么样 申请店铺

我要投票 乐普LEPU在医疗器械行业中的票数:291 更新时间:2025-04-27
乐普LEPU是哪个国家的品牌?「乐普LEPU」是乐普(北京)医疗器械股份有限公司旗下著名品牌。该品牌发源于北京市,由创始人蒲忠杰在1999-06-11期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力乐普LEPU品牌出海!通过在本页面挂载乐普LEPU品牌的产品链接和联系方式,可以提高乐普LEPU产品曝光!跨境电商爆单神器,目前只要100元/年哦~

乐普LEPU怎么样

创立于1999年,集产品研发、生产、销售于一体,专业从事植介入诊疗器械及设备领域的医疗产品产业集团,其心血管病植介入诊疗器械在业内颇具影响力

乐普(北京)医疗器械股份有限公司(简称乐普医疗集团)创立于1999年,股份制集团上市公司(股票代码300003),公司销售网络遍布全中国及95个国家和地区,年营业收入46亿元人民币。 通过坚持技术创新、合作共赢的发展之路,乐普医疗集团正努力建立四位一体的心血管全产业链平台型企业。

乐普(北京)医疗器械股份有限公司创立于1999年,总部位于北京市中关村科技园区昌平园。公司是从事冠状动脉药物支架、先心封堵器、心脏瓣膜、造影机等心血管疾病植介入诊疗器械及设备产品研发、生产与销售的中外合资央企控股企业,是2009年在深交所创业板上市的28家企业之一。公司目前拥有国内外8家子公司,产品临床应用覆盖全国1200家以上心脏诊疗中心,已发展成为国内从事的心血管病植介入诊疗器械与设备的医疗产品产业集团。

乐普公司集合了材料、机械、电子、精密加工、临床医学等各类专业人才,拥有一支在产品研发、质量控制、临床验证、市场开拓、企业管理等方面专业的经验丰富的人才队伍。研制开发涵盖:冠心病、结构性心脏病、心脏节律、预先和术后诊断及诊疗设备五大领域的植介入产品,取得了一系列具有国内、国际水平的研究成果。是国内规模较大的也是拥有多种技术特点药物支架产品的制造企业,是亚洲较大的人工心脏瓣膜制造企业,是国内心脏起搏器的先行者,是国内心脏封堵器、血管造影机的市场佼佼者,是国内研制肾动脉射频消融导管的企业。

乐普公司疗创立以来,先后承担了国家发改委高技术产业化示范工程项目、国家科技部863计划发展项目、科技支撑计划项目等几十项国家重大课题。2013年,以乐普公司为依托单位,组建了“国家心脏病植介入诊疗器械及设备工程技术研究中心”,将进一步推动建设国家心脏病植介入诊疗器械及设备技术创新、产业化和人才聚集的平台,攻克一系列行业发展的核心技术和核心工艺,推动我国心脏病植介入医疗事业的迅速发展。我们秉承“以科技的力量,从心点燃生命的光辉”,为广大医护工作者提供更好更强的医疗产品与技术,使更多心血管病患者能够用得上用得起中国自己的医疗技术和产品。


Founded in 1999, it is a medical product industry group integrating product R & D, production and sales, specializing in the field of interventional devices and equipment. Its cardiovascular interventional devices have great influence in the industry. Lepu (Beijing) Medical Devices Co., Ltd. (referred to as Lepu medical group) was founded in 1999. The joint stock group listed company (Stock Code: 300003) )The company's sales network covers all over China and 95 countries and regions, with an annual operating revenue of 4.6 billion yuan. By adhering to the development path of technological innovation and win-win cooperation, Lepu medical group is striving to establish a platform enterprise of four in one cardiovascular industry chain. Lepu (Beijing) medical equipment Co., Ltd. was founded in 1999 and its headquarter is located in Changping Park, Zhongguancun Science and Technology Park, Beijing. The company is a Sino foreign joint-venture state-owned enterprise holding the R & D, production and sales of cardiovascular disease interventional devices and equipment products, such as coronary drug stent, precordial occluder, heart valve and contrast machine. It is one of the 28 enterprises listed on the growth enterprise market of Shenzhen Stock Exchange in 2009. At present, the company has 8 subsidiaries at home and abroad, with clinical application covering more than 1200 cardiac diagnosis and treatment centers across the country, and has developed into a domestic medical product industry group engaged in cardiovascular interventional diagnosis and treatment equipment and equipment. Lepu company has gathered all kinds of professional talents in materials, machinery, electronics, precision processing, clinical medicine, etc., and has a professional team with rich experience in product research and development, quality control, clinical verification, market development, enterprise management, etc. The research and development covers five fields: coronary heart disease, structural heart disease, heart rhythm, pre and post-operative diagnosis and treatment equipment, and a series of research results with domestic and international level have been achieved. It is a large-scale manufacturing enterprise with a variety of technical characteristics of drug stent products in China, a large artificial heart valve manufacturing enterprise in Asia, a pioneer in domestic cardiac pacemaker, a market leader in domestic cardiac occluder and angiograph, and a domestic enterprise in the research and development of renal artery radiofrequency catheter ablation. Since its establishment, Lepu company has successively undertaken dozens of national major projects, such as the high-tech industrialization demonstration project of the national development and Reform Commission, the 863 program development project of the Ministry of science and technology, and the science and technology support program project. In 2013, with Lepu company as the supporting unit, the "National Center for engineering and technology research of heart disease plant intervention diagnosis and treatment equipment and equipment" was established, which will further promote the construction of a national platform for innovation, industrialization and talent accumulation of heart disease plant intervention diagnosis and treatment equipment and equipment, attack a series of core technologies and core processes for industry development, and promote China's heart disease plant intervention medical affairs The rapid development of the industry. We adhere to the principle of "lighting up the brilliance of life from the heart with the power of science and technology" to provide better and stronger medical products and technologies for medical workers, so that more patients with cardiovascular diseases can use their own medical technologies and products in China.

本文链接: https://brand.waitui.com/56660df8a.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

格力电器:2024年归母净利润同比增长10.91%,拟10派20元

36氪获悉,格力电器4月27日公告,2024年营业收入1891.64亿元,同比下降7.26%;归母净利润321.85亿元,同比增长10.91%,基本每股收益5.83元。公司拟每10股派发现金红利20元(含税)。同日披露的2025年一季报显示,公司一季度实现营业收入415.07亿元,同比增长14.14%;归母净利润59.04亿元,同比增长26.29%。

2小时前

泸州老窖:2024年净利润同比增长1.71%,拟10派45.92元

36氪获悉,泸州老窖公告,公司2024年实现营业收入311.96亿元,同比增长3.19%,净利润134.73亿元,同比增长1.71%;基本每股收益9.18元。公司拟每10股派发现金红利45.92元(含税)。泸州老窖同日披露2025年一季报,一季度实现净利润45.93亿元,同比增长0.41%。

2小时前

商务部副部长盛秋平:将打造一批国际消费集聚区和入境消费友好商圈

商务部副部长盛秋平4月27日在国新办发布会上表示,商务部将继续深化国际消费中心城市建设,支持推动扩大入境消费。商务部将打造国际化消费环境,指导各地优化涉外支付服务,提升离境退税政策效能,打造一批国际消费集聚区和入境消费友好商圈,打通外国人在华消费堵点、痛点。近期财政部门正积极研究对有关方面给予专项资金支持。(证券时报)

2小时前

中金公司:美图生活场景国内付费渗透率达5.2%

36氪获悉,中金公司研报透露,预计截至2月,美图公司生活场景下的国内付费渗透率已经达到5.2%。该场景下的产品包括美图秀秀、美颜相机、Wink等。据研报显示,美图生活场景产品国内付费渗透率突破5%,主要得益于生成式AI对传统功能的重新构建,如用AI去双下巴取代传统的手动推图,带来更好的用户体验和效果,促进订阅转化率提升。美图对生活场景应用订阅渗透率的长期目标为10%。

2小时前

惠誉博华:商业银行扩表节奏趋缓

36氪获悉,近日惠誉博华商业银行2024年度业绩点评。报告显示,2024年商业银行总资产同比增速回落至4.8%,结束此前连续三年的双位数扩张周期。从银行机构类型看呈现显著分化态势:城商行以8.9%的资产增速领跑,农商行以6.0%的增速紧随其后,国有大行与股份制银行分别录得3.9%和2.7%的增速。这种梯度差异映射出不同类别银行面临的经营环境——头部城商行凭借区域经济韧性维持相对活跃的资产扩张,而股份制银行负债端受制于存款成本刚性约束难以匹配国有大行资金优势,资产端受风险偏好与定价能力限制难以深度渗透区域下沉市场,导致信贷资源配置效率持续承压,近三年资产增速中枢较2019至2021年下降逾6个百分点,信贷市场正从增量竞争向存量优化转换。

2小时前

本页详细列出关于乐普LEPU的品牌信息,含品牌所属公司介绍,乐普LEPU所处行业的品牌地位及优势。
咨询